Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer
Cardiff Oncology appointed Leila Alland, MD, as interim Chief Medical Officer, succeeding Roger Sidhu, MD, who has stepped down. Dr. Alland is a veteran oncology executive with prior CMO roles at PMV Pharma, Affimed and Tarveda, and leadership stints at AstraZeneca, Bristol Myers Squibb and Novartis contributing to approvals including Tagrisso and Opdivo.
Key figures
- Median pfs
- not reached in onvansertib 30 mg + FOLFIRI + bevacizumab arm
- Phase 3 start
- Q1 2027
- Patients on treatment
- 18+ months
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.